Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend Its SEC Reporting Obligations

Navidea Biopharmaceuticals, Inc. announced today the filing of Form 15 to voluntarily deregister and suspend SEC reporting obligations. The company maintains strategic focus on its Fix, Fund, Propel a

BusinesswireJan 27 08:05

Navidea Settles Litigation With Capital Royalty, Stock Rallies 30%

Seeking AlphaDec 2, 2023 01:03

Navidea Biopharmaceuticals, CRG Settle All Ongoing Litigation

RTTNewsDec 1, 2023 21:54

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation.DUBLIN, Ohio--(BUSINESS WIRE)--Na

BusinesswireDec 1, 2023 21:30

Sector Update: Health Care

Health care stocks were rising late Friday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each up about 1.2%. The iShares Biotechnology ETF (IBB) was addin

MT NewswiresOct 7, 2023 03:31

Top Midday Decliners

OmniQ (OMQS) shares slumped 48% after the company said it priced an underwritten public offering of 3 million common shares, or pre-funded warrants in lieu of common shares, at $1 per share for gross

MT NewswiresOct 7, 2023 02:14